{
  "id": 1774,
  "text": "74 $9 5 ~ \\mathrm { C I } = 0 .5 3 \\substack { - 1 .0 5 }$ , ${ \\bf p } = { \\bf \\Phi }$ 0.09).The response rates were $4 7 \\%$ and $2 7 \\% .$ , respectively $[ \\mathrm { p } = 0 .0 0 2 \\AA$ .It should be noted that as compared with cisplatin/paclitaxel (either with or without bevacizumab) topotecan/paclitaxel was associated with (1) a significantly higher risk of progression $[ \\mathrm { H R } =$ 1.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 74 $9 5 ~ \\mathrm { C I } = 0 .5 3 \\substack { - 1 .0 5 }$ , ${ \\bf p } = { \\bf \\Phi }$ 0.09).The response rates were $4 7 \\%$ and $2 7 \\% .$ , respectively $[ \\mathrm { p } = 0 .0 0 2 \\AA$ .It should be noted that as compared with cisplatin/paclitaxel (either with or without bevacizumab) topotecan/paclitaxel was associated with (1) a significantly higher risk of progression $[ \\mathrm { H R } =$ \n\n<question>: ",
  "ChatGPT_response_0": "根据研究，顺铂/紫杉醇与顶otecan/paclitaxel相比，无论是否使用贝伐珠单抗，进展风险更高。该研究发现顺铂/紫杉醇组的总体进展率较高，因此在选择化疗方案时需要考虑该因素。在治疗过程中，应充分了解不同方案的优缺点，综合考虑患者的具体情况和需求，做出合适的决定。",
  "query": "与顶otecan/paclitaxel相比，顺铂/紫杉醇（无论是否使用贝伐珠单抗）是否具有更高的进展风险？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 与顶otecan/paclitaxel相比，顺铂/紫杉醇（无论是否使用贝伐珠单抗）是否具有更高的进展风险？\n\n<reference text>: 74 $9 5 ~ \\mathrm { C I } = 0 .5 3 \\substack { - 1 .0 5 }$ , ${ \\bf p } = { \\bf \\Phi }$ 0.09).The response rates were $4 7 \\%$ and $2 7 \\% .$ , respectively $[ \\mathrm { p } = 0 .0 0 2 \\AA$ .It should be noted that as compared with cisplatin/paclitaxel (either with or without bevacizumab) topotecan/paclitaxel was associated with (1) a significantly higher risk of progression $[ \\mathrm { H R } =$ 1.\n\n<reply>: ",
  "response": "根据研究，顺铂/紫杉醇与顶otecan/paclitaxel相比，无论是否使用贝伐珠单抗，进展风险更高。该研究发现顺铂/紫杉醇组的总体进展率较高，因此在选择化疗方案时需要考虑该因素。在治疗过程中，应充分了解不同方案的优缺点，综合考虑患者的具体情况和需求，做出合适的决定。"
}